Log in

Relevant bibliographies by topics / Pharmaceutical biotechnology / Journal articles

To see the other types of publications on this topic, follow the link: Pharmaceutical biotechnology.

Journal articles on the topic 'Pharmaceutical biotechnology'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pharmaceutical biotechnology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Boulay, Jean-Louis, and Sylvie Miot. "Chemical biotechnology Pharmaceutical biotechnology." Current Opinion in Biotechnology 11, no. 6 (December 2000): 515. http://dx.doi.org/10.1016/s0958-1669(00)00138-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Boulay, Jean-Louis. "Pharmaceutical biotechnology: Chemical biotechnology." Current Opinion in Biotechnology 10, no. 6 (December 1999): 523–24. http://dx.doi.org/10.1016/s0958-1669(99)00022-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Roque-Borda, Cesar Augusto, Fernando Rogério Pavan, and Andréía Bagliotti Meneguin. "Pharmaceutical Biotechnology." Life 12, no. 8 (August 16, 2022): 1240. http://dx.doi.org/10.3390/life12081240.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Lawn, Richard M., and Laurence A. Lasky. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 11, no. 6 (December 2000): 579–80. http://dx.doi.org/10.1016/s0958-1669(00)00156-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

GUZMAN, C., and G. FEUERSTEIN. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 15, no. 6 (December 2004): 503–5. http://dx.doi.org/10.1016/s0958-1669(04)00147-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Liu, D. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 7, no. 6 (December 1996): 581–82. http://dx.doi.org/10.1016/s0958-1669(96)80067-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Knowles, Jonathan. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 8, no. 6 (December 1997): 667–68. http://dx.doi.org/10.1016/s0958-1669(97)80116-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Olson, Eric R., and Barry Ratzkin. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 10, no. 6 (December 1999): 525–27. http://dx.doi.org/10.1016/s0958-1669(99)00023-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Metcalf, Brian, and Rino Rappuoli. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 14, no. 6 (December 2003): 618–20. http://dx.doi.org/10.1016/j.copbio.2003.10.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

McCormick, Frank, and Wendell Wierenga. "Pharmaceutical biotechnology." Current Opinion in Biotechnology 6, no. 6 (January 1995): 621–23. http://dx.doi.org/10.1016/0958-1669(95)80102-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Ranade, Vasant V. "Biotechnology: Pharmaceutical Aspects." American Journal of Therapeutics 17, no. 1 (January 2010): 121. http://dx.doi.org/10.1097/mjt.0b013e31817c947a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Miot, Sylvie, and Jean-Louis Boulay. "Pharmaceutical biotechnology, Chemical biotechnology: Web alert." Current Opinion in Biotechnology 13, no. 6 (December 2002): 531–32. http://dx.doi.org/10.1016/s0958-1669(02)00383-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Pfeifer, Blaine A., Guojian Zhang, and Dehai Li. "Editorial overview: Pharmaceutical biotechnology." Current Opinion in Biotechnology 69 (June 2021): vi—viii. http://dx.doi.org/10.1016/j.copbio.2021.06.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Makalowski, W. "Web alert Pharmaceutical biotechnology." Current Opinion in Biotechnology 7, no. 6 (December 1996): 667. http://dx.doi.org/10.1016/s0958-1669(96)80080-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Makalowski, Wojciech, and Hervé Récipon. "Web alert Pharmaceutical biotechnology." Current Opinion in Biotechnology 8, no. 6 (December 1997): 659. http://dx.doi.org/10.1016/s0958-1669(97)80114-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Boulay, Jean-Louis, and Hervé Récipon. "Pharmaceutical biotechnology Web alert." Current Opinion in Biotechnology 9, no. 6 (December 1998): 557–58. http://dx.doi.org/10.1016/s0958-1669(98)80130-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Fussenegger, Martin. "Pharmaceutical Biotechnology (2nd Edition)." Drug Discovery Today 8, no. 17 (September 2003): 783–84. http://dx.doi.org/10.1016/s1359-6446(03)02801-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ivanov, I. "Pharmaceutical and Medical Biotechnology." Biotechnology & Biotechnological Equipment 21, no. 1 (January 2007): 74–79. http://dx.doi.org/10.1080/13102818.2007.10817418.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Liu, Tiangang, and Chu-Young Kim. "Editorial overview: Pharmaceutical biotechnology." Current Opinion in Biotechnology 48 (December 2017): 258–59. http://dx.doi.org/10.1016/j.copbio.2017.10.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lewis, Amanda M., and Nripen Singh. "Editorial overview: Pharmaceutical biotechnology." Current Opinion in Biotechnology 53 (October 2018): iii—iv. http://dx.doi.org/10.1016/j.copbio.2018.09.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Masson, Patrick, Carole Tonello, and Claude Balny. "High-Pressure Biotechnology in Medicine and Pharmaceutical Science." Journal of Biomedicine and Biotechnology 1, no. 2 (2001): 85–88. http://dx.doi.org/10.1155/s1110724301000158.

Full text

Abstract:

High-pressure (HP) biotechnology is an emerging technique initially applied for food processing and more recently in pharmaceutical and medical sciences. Pressure can stabilize enzymes and modulate both their activity and specificity. HP engineering of proteins may be used for enzyme-catalyzed synthesis of fine chemicals, pharmaceuticals, and production of modified proteins of medical or pharmaceutical interest. HP inactivation of biological agents is expected to be applicable to sterilization of fragile biopharmaceuticals, or medical compounds. The enhanced immunogenicity of some pressure-killed bacteria and viruses could be applied for making new vaccines. Finally, storage at subzero temperatures without freezing is another potential application of HP for cells, animal tissues, blood cells, organs for transplant, and so forth.

APA, Harvard, Vancouver, ISO, and other styles

22

de la Cueva-Méndez, Guillermo, and Dror Seliktar. "Editorial overview: Pharmaceutical biotechnology: Expanding horizons for pharmaceutical biotechnology in industry and academia." Current Opinion in Biotechnology 35 (December 2015): iv—vi. http://dx.doi.org/10.1016/j.copbio.2015.09.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

DOLENINA, Ol'ga E., and Viktoriya D. PEREVALOVA. "Innovative processes in the German pharmaceutical industry." Economic Analysis: Theory and Practice 22, no. 7 (July 31, 2023): 1384–96. http://dx.doi.org/10.24891/ea.22.7.1384.

Full text

Abstract:

Subject. The article addresses Germany's competitive position in the global pharmaceutical market and R&D development in the pharmaceutical industry. Objectives. The purpose is to provide a unique comprehensive study of innovative processes development in the pharmaceutical industry, using the case of German companies, explore innovative approaches to solving production problems, identify leading German companies in the field of biotechnology, and reveal the most promising areas for the development of German pharmaceuticals. Methods. We employ statistical and cartographic methods, and methods of comparative and economic analysis. Results. In their activities, German pharmaceutical companies combine the production of medicines, medical equipment, innovative developments, and implementation of various treatment, therapy and diagnostic programs. In a highly competitive global generic market, in Germany, there is a trend towards intra-industry structural transformation of pharmaceutical companies. The paper analyzed R&D spending, the geography of research centers of German pharmaceutical companies in the world, and their activities. Conclusions. The specifics of German pharmaceutical industry is the manufacture of high-tech products, using medical biotechnologies, which provides the country's advantage in the world market. Despite the presence of competitors in the generic market, i.e. India and China, German biotechnology-based pharmaceuticals continue to be in high demand among consumers as a high-quality product.

APA, Harvard, Vancouver, ISO, and other styles

24

Yaseen, Arshed H., Halah M. H. Al-Hasani, and Umer Abdullah Ahmed Alelyan. "Biotechnology for medical diagnosis." Drug and Pharmaceutical Science Archives 02, no. 01 (2022): 01–05. http://dx.doi.org/10.47587/dpsa.2022.2101.

Full text

Abstract:

Biotechnology is broadly defined as, “using organisms or their products for commercial purposes” encompasses a wide range. Since the beginning of time, people have used (traditional) biotechnology. Wheat, brew alcohol, and breed food crops and domestic animals have all been made using this grain. Molecular biology’s most recent breakthroughs, on the other hand, have given new life to biotechnology’s relevance and potential. Biotechnology has become a hot topic among the general public. There’s a good chance that modern biotechnology will have a big impact on the environment. Small-molecule (chemical) medications produced by well-known pharmaceutical companies have traditionally accounted for the vast majority of human illness treatments. The current article discussed.

APA, Harvard, Vancouver, ISO, and other styles

25

Evens, Ronald P. "The Biotechnology Industry." Journal of Pharmacy Practice 11, no. 1 (February 1998): 13–18. http://dx.doi.org/10.1177/089719009801100104.

Full text

Abstract:

Growth and change are the hallmarks of the developing biotechnology industry. Since the first approval of a biological product in 1982, over 40 biologicals, many of them medical breakthroughs, have been brought to market. The majority of biotechnology companies focus on developing human therapeutic agents, but about 25 percent of biotechnology companies focus on the diagnostic area, using monoclonal antibody technology, polymerase chain reaction (PCR) technology, and genetics to provide advances in diagnosis and disease monitoring. Structurally, few biotechnology firms are fully integrated companies with full capabilities in research, development, manufacturing, and sales and marketing. Many pursue strategic alliances with other companies to enhance their capabilities in research, development, and sales and marketing. Research alliances between companies and universities are also frequently used to enhance research capabilities. As the industry has matured, consolidation has occurred, with major pharmaceutical companies purchasing biotechnology companies and biotechnology companies merging to expand their capabilities. Research investment, as a percentage of gross sales, continues to be very high for biotechnology companies compared with traditional pharmaceutical companies. The cost of drug development is high, but the probability of approval appears to be somewhat better in the biotechnology field compared with traditional pharmaceuticals. Today, the biotechnology product pipeline is rich, with between 400 to 700 products in various stages of clinical development. Technology developments beyond recombinant DNA technology and monoclonal antibodies, such as antisense, genomics, and combinatorial chemistry, will lead to additional therapeutic and diagnostic breakthroughs.

APA, Harvard, Vancouver, ISO, and other styles

26

Chiu, Robert I. T. "Biotechnology in Taiwan." Asia-Pacific Biotech News 06, no. 20 (September 30, 2002): 730–34. http://dx.doi.org/10.1142/s0219030302001556.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Bell, Jennifer. "Medical Writing explores the many faces of biotechnology." Medical Writing 32, no. 4 (December 11, 2023): 2–4. http://dx.doi.org/10.56012/zskr5275.

Full text

Abstract:

This Medical Writing issue focuses on the crucial role of medical writing and communications in biotechnology and product development in healthcare. In the pharmaceutical and medical device industries, biotechnology uses biological systems and living organisms in R&D and production processes for product development. Some biotechnologies include biologic and biosimilar pharmaceuticals, vaccines, and advanced therapy medicinal products, including gene and cell therapies and tissue engineered products.

APA, Harvard, Vancouver, ISO, and other styles

28

K. Zuba-Surma, Ewa, Alicja Jozkowicz, and Jozef Dulak. "Stem Cells in Pharmaceutical Biotechnology." Current Pharmaceutical Biotechnology 12, no. 11 (November 1, 2011): 1760–73. http://dx.doi.org/10.2174/138920111798377120.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Rubin, Suzie. "Biotechnology and the Pharmaceutical Industry." Cancer Investigation 11, no. 4 (January 1993): 451–57. http://dx.doi.org/10.3109/07357909309018876.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Boje, Kathleen MK, Christine Sauciunac, and Travis Piper. "A Pharmaceutical Biotechnology Virtual Laboratory." American Journal of Pharmaceutical Education 69, no. 2 (September 2005): 24. http://dx.doi.org/10.5688/aj690224.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ramirez, Octavio T., and Rodolfo Quintero. "Pharmaceutical biotechnology emerges in Mexico." Nature Biotechnology 17, no. 10 (October 1999): 934. http://dx.doi.org/10.1038/13587.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Lentz, Edward T. "Pharmaceutical and Biotechnology Research Revisited." Biotechnology Law Report 25, no. 1 (February 2006): 2–5. http://dx.doi.org/10.1089/blr.2006.25.2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Mallela, Krishna. "Pharmaceutical biotechnology - concepts and applications." Human Genomics 4, no. 3 (2010): 218. http://dx.doi.org/10.1186/1479-7364-4-3-218.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Baker, Danial E. "Pharmaceutical Biotechnology: A Programmed Text." American Journal of Health-System Pharmacy 50, no. 3 (March 1, 1993): 565–66. http://dx.doi.org/10.1093/ajhp/50.3.565.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Zito, S. William. "Pharmaceutical Biotechnology: A Programmed Text." Journal of Pharmacy Practice 10, no. 5 (October 1997): 328. http://dx.doi.org/10.1177/089719009701000507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Sidhu, Sachdev S. "Phage display in pharmaceutical biotechnology." Current Opinion in Biotechnology 11, no. 6 (December 2000): 610–16. http://dx.doi.org/10.1016/s0958-1669(00)00152-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kumari, Manisha. "Pharmaceutical biotechnology: Applications in medicine." Pharma Innovation 8, no. 1 (January 1, 2019): 910–13. http://dx.doi.org/10.22271/tpi.2019.v8.i1o.25496.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Boje, Kathleen M. K., Christine Sauciunac, and Travis Piper. "A Pharmaceutical Biotechnology Virtual Laboratory." American Journal of Pharmaceutical Education 69, no. 2 (2005): 24. http://dx.doi.org/10.1016/s0002-9459(24)08715-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Tabassum Samanta, Mahonaz, and Sadia Noor. "PROSPECTS AND CHALLENGES OF PHARMACEUTICAL BIOTECHNOLOGY." International Journal of Advanced Research 9, no. 01 (January 31, 2021): 709–29. http://dx.doi.org/10.21474/ijar01/12349.

Full text

Abstract:

Biotechnology is a broad area of biology, involving the use of living systems and organisms to develop products. Depending on the tools and applications, it often overlaps with related scientific fields. In the late 20th and early 21st centuries, biotechnology has expanded to include new and diverse sciences, such as genomics, recombinant gene techniques, applied immunology, and development of pharmaceutical therapies and diagnostic tests. Biotechnology has also led to the development of antibiotics. Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non-food (industrial) uses of crops and other products and environmental uses. In medicine, modern biotechnology has many applications in areas such as pharmaceutical drug discoveries and production, pharmacogenomics, and genetic testing. Pharmaceutical biotechnology is a relatively new and growing field in which the principles of biotechnology are applied to the development of drugs. A majority of therapeutic drugs in the current market are bio formulations, such as antibodies, nucleic acid products and vaccines. Such bio formulations are developed through several stages that include: understanding the principles underlying health and disease the fundamental molecular mechanisms governing the function of related biomolecules synthesis and purification of the molecules determining the product shelf life, stability, toxicity and immunogenicity drug delivery systems patenting and clinical trials. This review article describes the purpose of biotechnology in pharmaceutical industry, particularly pharmaceutical biotechnology along with its prospects and challenges.

APA, Harvard, Vancouver, ISO, and other styles

40

Roth, Ronica. "Specializing in Biotechnology Pharmaceuticals." American Pharmacy 34, no. 4 (April 1994): 31–33. http://dx.doi.org/10.1016/s0160-3450(15)30455-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Miller, Henry I. "Japanese Pharmaceutical Biotechnology: Perception vs. Reality." Nature Biotechnology 7, no. 7 (July 1989): 736. http://dx.doi.org/10.1038/nbt0789-736.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Acharya, Milin R., and William D. Figg. "Book Review: Handbook of Pharmaceutical Biotechnology." Annals of Pharmacotherapy 38, no. 1 (January 2004): 178. http://dx.doi.org/10.1345/aph.1d276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Malinowski, Michael J. "Pharmaceutical Medicine, Biotechnology and European Law." Journal of Legal Medicine 23, no. 1 (March 2002): 159–66. http://dx.doi.org/10.1080/019476402317276722.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Dibner, Mark D. "The pharmaceutical industry: impacts of biotechnology." Trends in Pharmacological Sciences 6 (January 1985): 343–46. http://dx.doi.org/10.1016/0165-6147(85)90158-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Galambos, Louis, and Jeffrey L. Sturchio. "Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation." Business History Review 72, no. 2 (1998): 250–78. http://dx.doi.org/10.2307/3116278.

Full text

Abstract:

During the twentieth century, the pharmaceutical industry experienced a series of dramatic changes as developments in science and technology generated new opportunities for innovation. Each of these transitions forced existing firms to develop new capabilities. The authors examine the most recent such transition, the shift to molecular genetics and recombinant DNA technology (1970 to the present), and explain how and why this transformation differed from the previous ones in pharmaceuticals. Small biotech startups played an important role in this transition, and the large pharmaceutical firms that began to enter the field had to develop new strategies for innovation. Two major strategies were adopted by the early movers, all of which created various kinds of alliances with the small biotech businesses. By the mid-1990s, the leading pharmaceutical manufacturers had established significant capabilities in the new field, but they were continuing to work with specialized biotechs in order to innovate across a broad range of therapeutic categories.

APA, Harvard, Vancouver, ISO, and other styles

46

Mamedyarov, Z. A. "Strategic Role of the Pharmaceutical Industry in the Сontext of the Global Pandemic." Journal of International Analytics 11, no. 4 (March 9, 2021): 122–36. http://dx.doi.org/10.46272/2587-8476-2020-11-4-122-136.

Full text

Abstract:

The strategic importance of the pharmaceutical industry for the scientific, technological and economic development of countries determines its impact on international processes. The paper traces the current trends in the growth of innovative competition in pharmaceuticals and biotechnology, taking into account the factor of the COVID-19 pandemic. The following areas of increased competition are highlighted: diversification of supply of active pharmaceutical substances, regulators’ permission of the newest drugs to access the market, competition of pharmaceutical companies for capital and competence. The pandemic has also exacerbated long-standing problems: the efficiency of drug distribution to citizens, the dependence of large manufacturers on active substance suppliers from China, drug pricing, and the role of social insurance systems in developed and developing countries. The article analyzes the main problems of the industry and presents possible trajectories of further development of international relations in the context of pharmaceuticals and biotechnology, analyzing the progress of creation and market admission of COVID-19 vaccines. For all the high-tech trends, the pharmaceutical industry is a rather conservative industry in which regulatory issues play a significant role. Therefore, legal, ethical and practical issues related to the collection of sensitive patient health data may slow down the digitalization of the pharmaceutical industry. Much will also depend on the decisions of major regulators – in the U.S. and the EU – regarding telemedicine and digital health in general. A serious barrier for the pharmaceutical industry is also the lack of pharmaceutical companies’ own experience in developing software solutions, which makes them dependent on external suppliers of IT solutions, complicates the problem of sharing clinical patient data and particularly raises the issue of cybersecurity.

APA, Harvard, Vancouver, ISO, and other styles

47

Birkinshaw, Julian, Ivanka Visnjic, and Simon Best. "Responding to a Potentially Disruptive Technology: How Big Pharma Embraced Biotechnology." California Management Review 60, no. 4 (June 5, 2018): 74–100. http://dx.doi.org/10.1177/0008125618778852.

Full text

Abstract:

How do incumbent firms respond over time to a potentially disruptive technology? This article documents the strategies of 12 large pharmaceutical firms over 25 years as they addressed the opportunity/threat of biotechnology. All showed awareness of biotechnology’s potential, but their response profiles varied dramatically in terms of timing (early/late) and focus (external/internal). Late movers mostly made large acquisitions to “catch up,” but early movers maintained their lead in terms of biotechnology-based drug sales and profitability, and those with a more “open” response profile performed better. This response involves a three-step process: building awareness (sensing), building capability (responding), and building commitment (scaling).

APA, Harvard, Vancouver, ISO, and other styles

48

Kolesar, Jill M. "Book Review: Pharmaceutical Biotechnology: An Introduction for Pharmacists and Pharmaceutical Scientists." Annals of Pharmacotherapy 33, no. 1 (January 1999): 119–20. http://dx.doi.org/10.1177/106002809903300102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Wertheimer, Albert I., and Sondra Grumer. "Therapeutic Applications and Economic Opportunities in the Biotechnologic Pharmaceutical Industry." Journal of Pharmacy Technology 9, no. 6 (November 1993): 249–53. http://dx.doi.org/10.1177/875512259300900605.

Full text

Abstract:

Objective To discuss the expected future development and implications of the US biotechnologic pharmaceutical industry. Foreign competition and internal forces that might impede the industry are also discussed. Data Sources Searches were conducted in the Business Periodicals Index and the International Pharmaceutical Abstracts databases. Study Selection All studies pertaining to the business of biotechnology were reviewed. Conclusions Biotechnologically produced agents will require a shorter period of development and a less costly production process, and will be generally safer than conventional drugs. Furthermore, these agents will afford superior pharmacotherapy to that of conventional drugs, enhancing the diagnosis and treatment of diseases as harrowing as AIDS and neoplastic disorders.

APA, Harvard, Vancouver, ISO, and other styles

50

Savitzky, Rodolfo J., and Klaus Möller. "Financial Leadership at Lonza." Controlling 33, no. 1 (2021): 75–78. http://dx.doi.org/10.15358/0935-0381-2021-1-75.

Full text

Abstract:

Lonza Group AG, based in Basel, Switzerland, manufactures active pharmaceutical ingredients, biotechnology products organic, fine chemicals and biocides. The Company offers custom chemical manufacturing and fermentation processing and manufactures its products for the life sciences, pharmaceuticals, food processing, and agricultural industries. Founded in 1897 Lonza has grown into a global chemicals and biotechnology business. The Company operates on 120 sites and offices in more than 35 countries with 15,500 full-time employees. In 2019, Lonza generated sales of CHF 5.9 bn with a CORE EBITDA of CHF 1.6 bn.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!